TERAPIAS-ALVO NO CÂNCER DE MAMA HER2-POSITIVO: EVIDÊNCIAS ATUAIS E PERSPECTIVAS FUTURAS

Read full text Summarise with VIRAT
Authors: Mariana Hirata, Geovanna de Castro Feitosa, Lívia Travessa Chambó, Mariana Valenhes dos Santos, Luca Gomes Ferreira de Oliveira
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

HER2-positive breast cancer is a biologically distinct subtype, historically associated with aggressive clinical behavior and poorer prognosis. Advances in understanding the molecular mechanisms related to HER2 receptor overexpression have enabled the development of targeted therapies, leading to significant changes in disease management. This chapter aimed to analyze, through a narrative literature review, the main evidence regarding targeted therapies in HER2-positive breast cancer and to discuss future perspectives in this field. The literature search was conducted in the PubMed, SciELO, ScienceDirect, and LILACS databases, including studies published between 2010 and 2024. The results demonstrate that the use of monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates has led to significant improvements in overall survival and progression-free survival, both in early-stage and metastatic disease. Additionally, new therapeutic strategies and drug combinations are being investigated to overcome resistance mechanisms and enhance treatment personalization. It is concluded that anti-HER2 targeted therapies represent a fundamental pillar in contemporary oncological care, with promising perspectives for optimizing clinical outcomes and advancing personalized medicine.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Gastric Cancer Management and Outcomes

Publication details

Pages
69–76
Publication date
24 March 2026
Language
EN
Document type
Book chapter